1072902-75-0

Basic information

• Product Name: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester
• Synonyms: L-Isoleucine Orlistat;N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester;Orlistat USP Related Compound E
• CAS NO: 1072902-75-0
• Molecular Formula: C29H53NO5
• Molecular Weight: 495.73482
• Product Categories: Chiral Reagents;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Chiral Reagents, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1072902-75-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(1072902-75-0)
• EPA Substance Registry System: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(1072902-75-0)

Safety Data

• Hazardous Substances Data: 1072902-75-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester is used as a pharmaceutical compound for its potential therapeutic effects. The molecule's unique structure allows it to interact with specific biological targets, making it a candidate for the development of new drugs.
Used in Research and Development:
In the field of research and development, N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester serves as a valuable tool for studying the interactions between molecules and their biological targets. Its unique properties can help researchers understand the mechanisms of various diseases and develop targeted therapies.
Used in Drug Design:
N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester is used in drug design as a starting point for the development of new pharmaceuticals. Its structural features can be modified to create more potent and selective compounds with improved pharmacological properties.
Used in Chemical Synthesis:
In the chemical synthesis industry, N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester can be used as a building block for the synthesis of more complex molecules. Its unique functional groups and stereochemistry make it a versatile component in the creation of novel compounds with various applications.
Used in Cosmetics Industry:
N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester may also find applications in the cosmetics industry, where it could be used as an active ingredient in skincare products. Its potential to interact with biological targets may provide benefits for skin health and appearance.

Upstream product

• 1072902-95-4 L-isoleucine-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester 
• 2258-42-6 formyl acetic anhydride 
• 1072902-88-5 N-[(phenylmethoxy)carbonyl]-L-isoleucine-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester 
• 1558-67-4 formic anhydride 
• 73-32-5 L-isoleucine 
• 3160-59-6 N-Cbz-L-Isoleucine 
• 104871-99-0 (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one 

Relevant articles and documents

NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF

The invention provides for novel lipase inhibitors, and compositions and devices comprising the same. The invention further provides for methods for treatment o f disorders comprising administration o f novel diacylglycerol lipase inhibitors, and com -positions and devices comprising said inhibitors. In some embodiments, the disorders are pancreatitis, obesity, shock or pancreatic necrosis. The invention further provides for novel ether lipid reporter compounds and methods o f assaying enzymatic activity com -prising contacting a compound with a novel ether lipid reporter compound.

Assay and inhibition of diacylglycerol lipase activity

A series of N-formyl-α-amino acid esters of β-lactone derivatives structurally related to tetrahydrolipstatin (THL) and O-3841 were synthesized that inhibit human and murine diacylglycerol lipase (DAGL) activities. New ether lipid reporter compounds were developed for an in vitro assay to efficiently screen inhibitors of 1,2-diacyl-sn-glycerol hydrolysis and related lipase activities using fluorescence resonance energy transfer (FRET). A standardized thin layer chromatography (TLC) radioassay of diacylglycerol lipase activity utilizing the labeled endogenous substrate [1″- 14C]1-stearoyl-2-arachidonoyl-sn-glycerol with phosphorimaging detection was used to quantify inhibition by following formation of the initial product [1″-14C]2-arachidonoylglycerol and further hydrolysis under the assay conditions to [1-14C]arachidonic acid.

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism

A series of 21 analogues of tetrahydrolipstatin (THL, 1) were synthesized and tested as inhibitors of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Three of the novel compounds, i.e., 11, 13, and 15, inhibited 2-AG formation via the diacylglycerol lipase α (DAGLα) with IC50 values lower than 50 nM (IC50 of THL = 1 μM) and were between 23- and 375-fold selective vs 2-AG hydrolysis by monoacylglycerol lipase (MAGL) as well as vs cannabinoid CB1 and CB2 receptors and anandamide hydrolysis by fatty acid amide hydrolase (FAAH). Three other THL analogues, i.e., 14, 16, and 18, were slightly more potent than THL against DAGLα and appreciably selective vs MAGL, CB receptors, and FAAH (15-26-fold). One compound, i.e., 8, was a potent inhibitor of MAGL-like activity (IC50 = 0.41 μM), and relatively (～7-fold) selective vs the other targets tested.